--- title: "3 Promising ASX Penny Stocks With Over A$60M Market Cap" type: "News" locale: "en" url: "https://longbridge.com/en/news/290907667.md" description: "The article highlights three ASX stocks with market caps over A$60M: Diatreme Resources (mineral exploration, pre-revenue but reducing losses), Mesoblast (regenerative medicine, unprofitable but optimizing capital structure with a pivotal Phase 3 trial), and United Overseas Australia (property development, strong asset coverage and earnings growth despite low ROE). These picks are presented as opportunities for value and upside amid global volatility." datetime: "2026-06-26T03:08:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290907667.md) - [en](https://longbridge.com/en/news/290907667.md) - [zh-HK](https://longbridge.com/zh-HK/news/290907667.md) --- # 3 Promising ASX Penny Stocks With Over A$60M Market Cap As Australian shares edge up slightly, defying global market volatility, investors are keenly watching for opportunities that align with current economic conditions. Penny stocks, while an old term, remain a relevant investment area for those seeking value in smaller or less-established companies. By focusing on robust financials and growth potential, these stocks can offer both stability and upside—qualities that make them attractive to investors looking to uncover hidden value in the market. Let's explore several standout options from the results in the screener. ## Diatreme Resources (ASX:DRX) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Diatreme Resources Limited, along with its subsidiaries, focuses on the exploration and development of mineral properties in Australia and has a market capitalization of A$60.10 million. **Operations:** The company generates revenue primarily from its exploration activities in heavy mineral sands, copper, gold, and base metals, totaling A$0.19 million. **Market Cap:** A$60.1M Diatreme Resources, with a market cap of A$60.10 million, is currently pre-revenue, generating A$0.19 million primarily from exploration activities. Despite being unprofitable, the company has reduced its losses by 24.7% annually over the past five years and maintains more cash than debt with short-term assets covering both short- and long-term liabilities. However, it faces financial constraints with less than a year of cash runway based on current free cash flow trends and lacks significant revenue streams to offset these challenges. The board is experienced but management tenure details are insufficient for assessment. - Click here to discover the nuances of Diatreme Resources with our detailed analytical financial health report. - Explore historical data to track Diatreme Resources' performance over time in our past results report. ASX:DRX Debt to Equity History and Analysis as at Jun 2026 ## Mesoblast (ASX:MSB) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Mesoblast Limited, along with its subsidiaries, focuses on developing regenerative medicine products across Australia, the United States, Singapore, and Switzerland with a market cap of A$2.70 billion. **Operations:** The company generates revenue from the development of its cell technology platform for commercialization, amounting to $65.38 million. **Market Cap:** A$2.7B Mesoblast Limited, with a market cap of A$2.70 billion, focuses on regenerative medicine and is currently unprofitable. The company has reduced its losses over the past five years and maintains more cash than debt, with short-term assets exceeding liabilities. Recent developments include drawing down US$50 million from a new debt facility to optimize capital structure by retiring higher-cost debt. Mesoblast's ongoing Phase 3 trial for rexlemestrocel-L in chronic low back pain could be pivotal for future revenue streams, given its potential blockbuster status if successful. Management and board members are seasoned, enhancing strategic execution capabilities. - Click to explore a detailed breakdown of our findings in Mesoblast's financial health report. - Gain insights into Mesoblast's future direction by reviewing our growth report. ASX:MSB Debt to Equity History and Analysis as at Jun 2026 ## United Overseas Australia (ASX:UOS) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** United Overseas Australia Ltd operates in the property investment and development sectors across Malaysia, Singapore, Vietnam, and Australia with a market cap of A$1.18 billion. **Operations:** The company generates revenue primarily from its Land Development and Resale segment, which accounts for A$468.18 million, and its Investment segment, contributing A$267.43 million. **Market Cap:** A$1.18B United Overseas Australia Ltd, with a market cap of A$1.18 billion, has demonstrated financial resilience despite recent executive changes following the passing of its Managing Director. The company benefits from strong asset coverage, with short-term assets of A$1.5 billion exceeding both short and long-term liabilities significantly. Its debt is well-managed, covered by operating cash flow, and it holds more cash than total debt. Although impacted by a large one-off gain recently, UOA's earnings growth over the past year outpaced industry averages at 60.4%. However, its Return on Equity remains low at 7%, indicating room for improvement in profitability metrics. - Click here and access our complete financial health analysis report to understand the dynamics of United Overseas Australia. - Gain insights into United Overseas Australia's past trends and performance with our report on the company's historical track record. ASX:UOS Debt to Equity History and Analysis as at Jun 2026 ## Taking Advantage - Embark on your investment journey to our 401 ASX Penny Stocks selection here. - Ready For A Different Approach? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [DRX.AU](https://longbridge.com/en/quote/DRX.AU.md) - [MSB.AU](https://longbridge.com/en/quote/MSB.AU.md) - [MESO.US](https://longbridge.com/en/quote/MESO.US.md) - [UOS.AU](https://longbridge.com/en/quote/UOS.AU.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [ASX Growth Stocks With High Insider Confidence](https://longbridge.com/en/news/294612583.md) - [Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline](https://longbridge.com/en/news/294369651.md) - [3 ASX Penny Stocks With At Least A$500M Market Cap](https://longbridge.com/en/news/294612589.md) - [Navigator Global Investments And 2 More ASX Stocks That May Be Trading Below Estimated Value](https://longbridge.com/en/news/294248241.md) - [ASX Dividend Stocks Yielding Up To 9.5%](https://longbridge.com/en/news/294612588.md)